



## **Market release**

23 April 2019

## **Clarification**

AFT Pharmaceuticals notes that the Sunday Star Times interviewed AFT's founder and CEO Dr Hartley Atkinson for an article which appeared in the Sunday Star Times print edition on 21 April and online on [stuff.co.nz](http://stuff.co.nz):

<https://www.stuff.co.nz/business/industries/112133823/new-zealand-drug-company-aft-prepares-to-sell-medical-cannabis-as-referendum-nears>

AFT wishes to clarify the comment attributed to Dr Atkinson that AFT would return to profitability in May when it releases its 2019 annual results. Dr Atkinson in fact commented that AFT is expected, as previously noted to the market on several occasions, to return to EBITDA profitability for FY19. This is likely to be confirmed to the market upon release of AFT's annual results for FY19 on 22 May 2019.

[End of Release]

For more information:

Dr Hartley Atkinson,  
CEO, AFT Pharmaceuticals Ltd  
Phone: +64 9 488 0232  
Email: [hartley@aftpharm.com](mailto:hartley@aftpharm.com)

**About AFT**

AFT is a growing multinational pharmaceutical business with a broad range of products, both developed itself and in-licensed from third parties. AFT's products cover all major pharmaceutical distribution channels: over-the-counter, prescription and hospital. Historically, AFT's home markets have been Australia, New Zealand and South-East Asia. However the company is out-licensing its own products to licensees and distributors to sell in an increasing number of countries around the world. The company's intensive Research and Development programme forms the basis of its international sales strategy. For more information about the company, visit [aftpharm.com](http://aftpharm.com)